ArticleBMC cancer2017

Phase I dose-escalation study of pazopanib combined with bevacizumab in patients with metastatic renal cell carcinoma or other advanced tumors.

Sylvie Négrier et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.